CRISPR 기반 유전자 편집 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

CRISPR-based Gene Editing Market Growth & Trends:

The global CRISPR-based gene editing market size is anticipated to reach USD 9.14 billion by 2030 and is projected to grow at a CAGR of 14.73% from 2024 to 2030, according to a report by Grand View Research, Inc. This robust growth trajectory in the market is driven by several key factors, including the rising prevalence of genetic disorders, significant advancements in CRISPR technology, supportive regulatory frameworks, and increasing investments in biotechnology and healthcare research. Together, these elements create a dynamic environment for innovation and development.

Advancements in CRISPR technology have notably fueled market expansion. Researchers have made remarkable progress in developing more precise and efficient CRISPR systems, including CRISPR/Cas9, CRISPR/Cas12, and emerging base editing technologies. These innovations have broadened the scope of potential applications, extending from treating genetic disorders to formulating targeted therapies for various cancers and infectious diseases. The enhanced ability to edit genes with high specificity and minimal off-target effects has captured considerable interest from both pharmaceutical and biotechnology sectors, which are increasingly eager to leverage these groundbreaking technologies for therapeutic development.

Moreover, the growing emphasis on personalized medicine is significantly influencing the demand for CRISPR technologies. As the healthcare landscape shifts toward more individualized treatment approaches, the capability to edit genes with precision enables the creation of therapies tailored to the unique genetic profiles of patients. This paradigm shift in medicine is likely to further accelerate the adoption of CRISPR technologies, as they provide unparalleled opportunities to develop targeted and effective treatments that can dramatically improve patient outcomes.

Supportive regulatory frameworks are fostering a conducive environment for research and commercialization. Regulatory bodies are increasingly recognizing the potential of CRISPR technologies, leading to streamlined approval processes that encourage innovation. Overall, the confluence of these factors positions the market for continued growth and innovation in the coming years, paving the way for revolutionary advancements in healthcare and biotechnology.

CRISPR-based Gene Editing Market Report Highlights:

• The products segment, which includes CRISPR kits and reagents, CRISPR libraries, and other related tools, led the market with the largest revenue share of 73.96% in 2023
• Based on application, the biomedical segment led the market with the largest revenue share of 81.83% in 2023 and is also projected to witness at the fastest CAGR of 15.09% during the forecast period. This growth is fueled by several key drivers, including the increasing prevalence of genetic disorders and cancers, alongside significant advancements in CRISPR technology
• Based on end use, the pharmaceutical & biotechnology companies segment led the market with the largest revenue share of 46.31% in 2023

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. CRISPR-based Gene Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of genetic disorders
    • 3.2.1.2. Growing investments in biotechnology and healthcare research
    • 3.2.1.3. Advancements in CRISPR technology and applications
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Ethical concerns surrounding gene editing
    • 3.2.2.2. High costs associated with CRISPR research and development
• 3.3. CRISPR-based Gene Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. CRISPR-based Gene Editing Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
• 4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Products
  • 4.4.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. CRISPR Kits & Reagents
    • 4.4.2.1. CRISPR kits & reagents market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. CRISPR Libraries
    • 4.4.3.1. CRISPR libraries market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. CRISPR-based Gene Editing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
• 5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Biomedical
  • 5.4.1. Biomedical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Therapeutic Development
    • 5.4.2.1. Therapeutic development market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2.2. By Indication
      • 5.4.2.2.1. Genetic Disorders
        • 5.4.2.2.1.1. Genetic Disorders market estimates and forecasts, 2018 to 2030 (USD Million)
      • 5.4.2.2.2. Oncology
        • 5.4.2.2.2.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
      • 5.4.2.2.3. Ophthalmology
        • 5.4.2.2.3.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
      • 5.4.2.2.4. Others
        • 5.4.2.2.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2.3. By Delivery Method
      • 5.4.2.3.1. Ex Vivo
      • 5.4.2.3.2. Ex vivo market estimates and forecasts, 2018 to 2030 (USD Million
      • 5.4.2.3.3. In Vivo
      • 5.4.2.3.4. In vivo market estimates and forecasts, 2018 to 2030 (USD Million
  • 5.4.3. Disease Diagnostics
    • 5.4.3.1. Disease diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Agricultural applications
  • 5.5.1. Agricultural applications market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.2. Plant Engineering
    • 5.5.2.1. Plant engineering market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.3. Farm Animals Engineering
    • 5.5.3.1. Farm animals engineering market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. CRISPR-based Gene Editing Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global CRISPR-based Gene Editing Market End-use Movement Analysis
• 6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Contract Research Organizations
  • 6.6.1. Contract research organizations market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. CRISPR-based Gene Editing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Target disease prevalence
    • 7.4.2.4. Regulatory framework
    • 7.4.2.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Target disease prevalence
    • 7.4.3.4. Regulatory framework
    • 7.4.3.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Target disease prevalence
    • 7.4.4.4. Regulatory framework
    • 7.4.4.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Target disease prevalence
    • 7.5.2.4. Regulatory framework
    • 7.5.2.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Target disease prevalence
    • 7.5.3.4. Regulatory framework
    • 7.5.3.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Target disease prevalence
    • 7.5.4.4. Regulatory framework
    • 7.5.4.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Target disease prevalence
    • 7.5.5.4. Regulatory framework
    • 7.5.5.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Target disease prevalence
    • 7.5.6.4. Regulatory framework
    • 7.5.6.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Target disease prevalence
    • 7.5.7.4. Regulatory framework
    • 7.5.7.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Target disease prevalence
    • 7.5.8.4. Regulatory framework
    • 7.5.8.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Target disease prevalence
    • 7.5.9.4. Regulatory framework
    • 7.5.9.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Target disease prevalence
    • 7.6.2.4. Regulatory framework
    • 7.6.2.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Target disease prevalence
    • 7.6.3.4. Regulatory framework
    • 7.6.3.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Target disease prevalence
    • 7.6.4.4. Regulatory framework
    • 7.6.4.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Target disease prevalence
    • 7.6.5.4. Regulatory framework
    • 7.6.5.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Target disease prevalence
    • 7.6.6.4. Regulatory framework
    • 7.6.6.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Target disease prevalence
    • 7.6.7.4. Regulatory framework
    • 7.6.7.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Target disease prevalence
    • 7.7.2.4. Regulatory framework
    • 7.7.2.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Target disease prevalence
    • 7.7.3.4. Regulatory framework
    • 7.7.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Target disease prevalence
    • 7.8.2.4. Regulatory framework
    • 7.8.2.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Target disease prevalence
    • 7.8.3.4. Regulatory framework
    • 7.8.3.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Target disease prevalence
    • 7.8.4.4. Regulatory framework
    • 7.8.4.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Target disease prevalence
    • 7.8.5.4. Regulatory framework
    • 7.8.5.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. List of Key Buyers for CRISPR-based Gene Editing Products & Services
• 8.5. Company Profiles/Listing
  • 8.5.1. Revvity, Inc.
    • 8.5.1.1. Company overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product/Service benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. Danaher Corporation
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product/Service benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. GenScript
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product/Service benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Merck KGaA
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product/Service benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Thermo Fisher Scientific, Inc.
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product/Service benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Tocris Bioscience
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product/Service benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. OriGene Technologies, Inc.
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product/Service benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Bio-Rad Laboratories
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product/Service benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Bio-Techne
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product/Service benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. New England Biolabs, Inc.
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product/Service benchmarking
    • 8.5.10.4. Strategic initiatives